We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Charles River Stock May Benefit From Joining EASYGEN Consortium
Read MoreHide Full Article
Key Takeaways
Charles River teams with EU's EASYGEN to deliver personalized CAR-T therapies faster and cheaper.
CRL leverages 3D screening and PDX models to fast-track safe, effective CAR-T therapy development.
Charles River stands to gain from rapid CAR-T market growth and rising cancer cases.
Charles River Laboratories International, Inc. (CRL - Free Report) is now part of the EASYGEN (Easy Workflow Integration for Gene Therapy) Consortium — a European Union-backed effort designed to produce CAR-T cell therapies faster, make them more affordable and widely accessible throughout Europe. The five-year research project is funded by the Innovative Health Initiative Joint Undertaking under grant agreement No 101194710, and involves collaboration among 18 leading academic, research, industry and clinical partners across eight countries.
The Consortium’s goal is to develop a fully automated, hospital-based platform capable of manufacturing personalized cell therapies within 24 hours.
CRL Stock’s Likely Trend Following the News
Since the announcement on Aug. 26, shares of Charles River dipped 0.2%, closing at $163.31 last Friday. Oncology remains a key therapeutic area for the company, where time is critical in treating complex cancers. With the current manufacturing process for CAR-T therapies being time-consuming and significantly limiting their clinical use, Charles River hopes to create a streamlined workflow by collaborating across industry and academia to increase access to these therapies for patients who need them. The latest development should positively boost market sentiment surrounding the stock.
Charles River has a market capitalization of $8.04 billion. The company’s earnings yield of 6.19% compares favorably with the industry’s 4.04% yield. In the trailing four quarters, it delivered an average earnings surprise of 12.8%.
More on Charles River’s Inclusion in EASYGEN
CAR-T cell therapy represents a major advancement in cancer treatment, yet less than 20% of eligible patients currently receive it. These therapies typically involve genetically altering a patient’s T cell to target cancer — a process that requires complex, time-intensive production in specialized facilities often located far from patients. Limited manufacturing capacity and supply-chain delays hinder timely patient access.
Image Source: Zacks Investment Research
Charles River will leverage its deep institutional expertise in 3D screening technologies to develop an ex vivo platform to speed up early screening for safety and efficacy. By leveraging access to the company’s well-annotated patient-derived xenograft (PDX) bank in combination with high-content imaging read-outs, the new 3D screening platform will enable the fast identification of the safest and most efficacious CAR-T cell candidate for subsequent development.
Industry Prospects Favoring Charles River
Per a Grand View Research report, the global CAR T-cell therapy market was valued at $4.65 billion in 2024 and is expected to grow at a compound annual rate of 22.2% through 2030. The rising cases of cancer malignancies continue to fuel the market for CAR T-cell therapy. Additionally, multiple product launches and approvals are giving market players significant traction. The lymphoma segment held the largest CAR T-cell therapy market share in 2024 and is also expected to be the fastest-growing segment over the forecast period.
Other Developments at Charles River
In July, CRL and BioTech Social Inc. announced that they are exploring a potential client-centric collaboration, enabling participants at the Charles River Incubator and Accelerator Program to access the BioTech Funding Portal — an investment crowdfunding platform for life science companies. If formalized, the contemplated strategic partnership would allow early-stage cell and gene therapy (CGT) developers to raise up to $5 million per year via the platform, accelerating development and enabling therapies to reach patients more quickly.
CRL Stock Price Performance
In the past year, Charles River shares have fallen 17.5% compared with the industry’s 17.3% decline.
Estimates for Envista’s 2025 earnings per share have increased 7.6% in the past 30 days. Shares of the company have rallied 16.7% in the past year compared with the industry’s 5.2% rise. Its earnings yield of 5.4% also outpaced the industry’s -0.9% yield. NVST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.5%.
Masimo shares have jumped 18.9% in the past year. Estimates for the company’s 2025 earnings per share have increased 5.2% to $5.24 in the past 30 days. MASI’s earnings beat estimates in each of the trailing four quarters, the average surprise being 13.8%. In the last reported quarter, it posted an earnings surprise of 8.1%.
Estimates for Phibro Animal Health’s fiscal 2026 earnings per share have climbed 5 cents to $2.35 in the past 30 days. Shares of the company have surged 76.5% in the past year compared with the industry’s 3.4% growth. PAHC’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 27.9%. In the last reported quarter, it delivered an earnings surprise of 9.6%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Charles River Stock May Benefit From Joining EASYGEN Consortium
Key Takeaways
Charles River Laboratories International, Inc. (CRL - Free Report) is now part of the EASYGEN (Easy Workflow Integration for Gene Therapy) Consortium — a European Union-backed effort designed to produce CAR-T cell therapies faster, make them more affordable and widely accessible throughout Europe. The five-year research project is funded by the Innovative Health Initiative Joint Undertaking under grant agreement No 101194710, and involves collaboration among 18 leading academic, research, industry and clinical partners across eight countries.
The Consortium’s goal is to develop a fully automated, hospital-based platform capable of manufacturing personalized cell therapies within 24 hours.
CRL Stock’s Likely Trend Following the News
Since the announcement on Aug. 26, shares of Charles River dipped 0.2%, closing at $163.31 last Friday. Oncology remains a key therapeutic area for the company, where time is critical in treating complex cancers. With the current manufacturing process for CAR-T therapies being time-consuming and significantly limiting their clinical use, Charles River hopes to create a streamlined workflow by collaborating across industry and academia to increase access to these therapies for patients who need them. The latest development should positively boost market sentiment surrounding the stock.
Charles River has a market capitalization of $8.04 billion. The company’s earnings yield of 6.19% compares favorably with the industry’s 4.04% yield. In the trailing four quarters, it delivered an average earnings surprise of 12.8%.
More on Charles River’s Inclusion in EASYGEN
CAR-T cell therapy represents a major advancement in cancer treatment, yet less than 20% of eligible patients currently receive it. These therapies typically involve genetically altering a patient’s T cell to target cancer — a process that requires complex, time-intensive production in specialized facilities often located far from patients. Limited manufacturing capacity and supply-chain delays hinder timely patient access.
Image Source: Zacks Investment Research
Charles River will leverage its deep institutional expertise in 3D screening technologies to develop an ex vivo platform to speed up early screening for safety and efficacy. By leveraging access to the company’s well-annotated patient-derived xenograft (PDX) bank in combination with high-content imaging read-outs, the new 3D screening platform will enable the fast identification of the safest and most efficacious CAR-T cell candidate for subsequent development.
Industry Prospects Favoring Charles River
Per a Grand View Research report, the global CAR T-cell therapy market was valued at $4.65 billion in 2024 and is expected to grow at a compound annual rate of 22.2% through 2030. The rising cases of cancer malignancies continue to fuel the market for CAR T-cell therapy. Additionally, multiple product launches and approvals are giving market players significant traction. The lymphoma segment held the largest CAR T-cell therapy market share in 2024 and is also expected to be the fastest-growing segment over the forecast period.
Other Developments at Charles River
In July, CRL and BioTech Social Inc. announced that they are exploring a potential client-centric collaboration, enabling participants at the Charles River Incubator and Accelerator Program to access the BioTech Funding Portal — an investment crowdfunding platform for life science companies. If formalized, the contemplated strategic partnership would allow early-stage cell and gene therapy (CGT) developers to raise up to $5 million per year via the platform, accelerating development and enabling therapies to reach patients more quickly.
CRL Stock Price Performance
In the past year, Charles River shares have fallen 17.5% compared with the industry’s 17.3% decline.
CRL’s Zacks Rank and Other Key Picks
Charles River carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks in the broader medical space include Envista (NVST - Free Report) , Masimo (MASI - Free Report) and Phibro Animal Health (PAHC - Free Report) . Each of them carries a Zacks Rank #2 at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Estimates for Envista’s 2025 earnings per share have increased 7.6% in the past 30 days. Shares of the company have rallied 16.7% in the past year compared with the industry’s 5.2% rise. Its earnings yield of 5.4% also outpaced the industry’s -0.9% yield. NVST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.5%.
Masimo shares have jumped 18.9% in the past year. Estimates for the company’s 2025 earnings per share have increased 5.2% to $5.24 in the past 30 days. MASI’s earnings beat estimates in each of the trailing four quarters, the average surprise being 13.8%. In the last reported quarter, it posted an earnings surprise of 8.1%.
Estimates for Phibro Animal Health’s fiscal 2026 earnings per share have climbed 5 cents to $2.35 in the past 30 days. Shares of the company have surged 76.5% in the past year compared with the industry’s 3.4% growth. PAHC’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 27.9%. In the last reported quarter, it delivered an earnings surprise of 9.6%.